Skip to main content

Prestige, Topic, and Team Size Sway Elite Journal Acceptance

A five-year analysis of 110,000-plus manuscripts finds prestige, topic, geography, and team size shaped who got published at Science and Science Advances.

Brought to you byThe Scientist
| 3 min read
Image shows a blue bar chart on a blue background, indicating a data story.
Register for free to listen to this article
Listen with Speechify
0:00
3:00

Elite general-science journals wield outsized influence over which discoveries reach the public, get cited by other scientists, and eventually shape health and science policy. Yet the mechanics behind who actually gets published remain largely opaque. “These journals play a special role in the science ecosystem, shaping what ideas get attention, inform society, and shape policy, yet very few studies have been able to open the black box and take a look at their review process,” said Aaron Clauset, a computer scientist at the University of Colorado Boulder, in a press release from the university.

Clauset and his team did exactly that in a study published in Science Advances, mining 110,303 manuscripts submitted to Science and Science Advances between 2015 and 2020.1 Only 6.1 percent of Science submissions and 10.5 percent of Science Advances submissions were ultimately accepted, and roughly three-quarters of manuscripts were rejected before a single outside reviewer ever saw them. What determined who cleared that first hurdle, the team found, had less to do with the science itself than with who was doing it, where they worked, and how many coauthors signed on.

What the Data Shows: Papers on Trending Topics Get in Six Times More Often

Horizontal bar chart titled “Elite Journals Reward Prestige, Popular Topics, and Big Teams.” Four red bars show how many times more likely a manuscript was to be accepted based on research topic (six times more likely for virus and immunity topics versus politics, economics, or gender studies), institutional prestige (3.4 times more likely for top-tier institutions), author location (three times more likely for US or Canada-based authors versus China-based authors), and team size (three times more likely for teams of ten or more authors versus teams of one to five).

An analysis of 110,303 manuscripts submitted to Science and Science Advances between 2015 and 2020 found that research topic, institutional prestige, author location, and team size each shaped a manuscript's odds of acceptance. Papers on viruses, infection, and immune-response topics were six times more likely to be accepted than those on politics, economics, or gender studies, the largest gap the analysis found.

Adapted from Zhang, et al, 2026. Image generated using Claude.

By the Numbers

  • 110,303 manuscripts submitted to Science and Science Advances (2015–2020) analyzed
  • 11.6 percent acceptance rate at top-tier institutions vs. 3.4 percent at lesser-known ones
  • 6 times more likely to be accepted: papers on viruses/immunity vs. politics, economics, or gender studies
  • 3 times more likely to be accepted: teams of 10+ authors vs. teams of 1–5

The pattern held across every dimension the team measured. Manuscripts from the most prestigious institutions were accepted 11.6 percent of the time, compared with 3.4 percent for papers from lesser-known institutions, more than a threefold gap. Authors based in China were more than three times less likely to be published than researchers at institutions in the US or Canada, and researchers with distinctly Chinese names faced a similar disadvantage even when they worked at US institutions, suggesting the bias tracked perceived identity as much as geography. Papers with 10 or more coauthors were three times as likely to be accepted as those with five or fewer authors.

Continue reading below...

Like this story? Sign up for FREE Newsletter updates:

Latest science news storiesTopic-tailored resources and eventsCustomized newsletter content
Subscribe

Manuscripts with women serving as corresponding author were accepted at a slightly lower rate than comparable papers led by men, a gap the authors estimated cost about 23 women-led papers a year at Science alone. “The fact that we find only a very marginal association with gender is in some sense reassuring,” Clauset said in the press release. “But the number is still not zero.”

Why It Matters: Peer Review Isn't the Meritocracy Scientists Assume

Clauset and his team were careful to note that their findings are correlational, not causal: institutional prestige, funding, and access to established collaborators are tangled together in ways submission data alone cannot fully untangle. But the size and consistency of the gaps, replicated across two journals with different acceptance thresholds and five years of data, complicate the assumption that peer review at elite general-science journals functions as a pure meritocracy. “With the rise of AI slop and the ability to mass produce junk science, the role of established gatekeepers like these elite journals becomes more important,” said Sam Zhang, a complex systems researcher at the University of Vermont and the study's first author, in the same press release. For early-career researchers and scientists outside a small circle of well-resourced institutions, the analysis offers a data-backed answer to a long-standing suspicion: getting published where it counts most depends only partly on the work itself.

Use of AI Declaration: This article was produced under The Scientist’s AI Editorial Policy.

  1. Zhang S, et al. Editorial and peer review dynamics at elite general science journals. Sci Adv. 2026;12(29):eaec0494.
Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Related Topics

You might also be interested in...
Loading Next Article...
You might also be interested in...
Loading Next Article...
The Scientist October Digest cover
October 2026

Antarctica’s Blood Falls Teems With Mysterious Microbial Life

Miles away from the closest ocean, marine microbes thrive in the red ice and mud around Blood Falls, offering clues to microbial adaptation and past climate events.

View this Issue
Evaluating Blood Biomarkers for Alzheimer’s Disease Staging

Evaluating Blood Biomarkers for Alzheimer’s Disease Staging

​Beckman Coulter
Find better biologics faster with Stunner and the AI Developability Workcell

Find better biologics faster with Stunner and the AI Developability Workcell

Unchained Labs
An image of microcentrifuge tubes arranged within colorful laboratory racks.

Choose clarity. Choose speed. Choose MyMass™

Refeyn
Characterizing LNP Heterogeneity With Super-Resolution Imaging

Characterizing LNP Heterogeneity With Super-Resolution Imaging

Oni

Products

Stellaromics Logo

Stellaromics Expands Pyxa Adoption as Instruments are Installed at Leading Research Institutions Across the U.S. and EuropeStellaromics, Inc., the leader in 3D

A monoclonal antibody surrounded by immune cells and red blood cells

CellRaft AIR: Find the Right Antibody-Producing Cells Faster

Cell Microsystems
Maxwell® Rapid ccfDNA Kit

Maxwell® Rapid ccfDNA Kit: Automated Purification of ccfDNA in Under 30 Minutes

Promega
Leica Biosystems, Tempus, and Paige logos side by side, marking the addition of Paige digital pathology AI tools to the Aperio AI Store.

Oncology Researchers Gain AI Cancer Tools in One Platform